Neuren Pharmaceuticals Limited
OTC: NURPF0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Other OTC
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Jonathan Charles Pilcher
- Employees
- 8
- Headquarters
- Camberwell, Australia
- IPO year
- 2009
- Market cap
- $1.1B
- Website
- https://www.neurenpharma.com
Loading NURPF…
Loading profile data…Frequently asked questions about NURPF
What does Neuren Pharmaceuticals Limited (NURPF) do?
Neuren Pharmaceuticals Limited is a biopharmaceutical company specializing in the development of treatments for neurological conditions. Their leading therapeutic compound, trofinetide, is currently undergoing pivotal (Phase III) clinical trials for Rett syndrome, and has also successfully completed Phase II trials targeting Fragile X syndrome....
Where does NURPF trade?
Neuren Pharmaceuticals Limited (NURPF) trades on the Other OTC.
What sector is NURPF in?
Neuren Pharmaceuticals Limited (NURPF) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Neuren Pharmaceuticals Limited?
Jonathan Charles Pilcher is the chief executive officer of Neuren Pharmaceuticals Limited (NURPF).
Where is Neuren Pharmaceuticals Limited headquartered?
Neuren Pharmaceuticals Limited is headquartered in Australia.
Does NURPF pay a dividend?
Neuren Pharmaceuticals Limited (NURPF) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did NURPF go public?
Neuren Pharmaceuticals Limited (NURPF) completed its initial public offering in 2009.